img

Global Immuno-oncology Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Immuno-oncology Drugs Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.
The global Immuno-oncology Drugs market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Immuno-oncology Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Immuno-oncology Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Immuno-oncology Drugs is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Immuno-oncology Drugs include Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson and Novartis International AG, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Immuno-oncology Drugs, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Immuno-oncology Drugs by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Immuno-oncology Drugs market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Immuno-oncology Drugs market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem, Inc.
Lonza Group
Bio-Rad Laboratories, Inc.
Avantor, Inc.
Spring Bank Pharmaceuticals, Inc.
Ferring Pharmaceuticals
By Type
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
By Application
Hospitals
Clinics
Ambulatory Surgical Centers
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Immuno-oncology Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Immuno-oncology Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-oncology Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Immuno-oncology Drugs Definition
1.2 Market by Type
1.2.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Immune System Modulators
1.2.4 Cancer Vaccines
1.2.5 Oncolytic Virus
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Immuno-oncology Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Immuno-oncology Drugs Sales
2.1 Global Immuno-oncology Drugs Revenue Estimates and Forecasts 2018-2034
2.2 Global Immuno-oncology Drugs Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Immuno-oncology Drugs Revenue by Region
2.3.1 Global Immuno-oncology Drugs Revenue by Region (2018-2024)
2.3.2 Global Immuno-oncology Drugs Revenue by Region (2024-2034)
2.4 Global Immuno-oncology Drugs Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Immuno-oncology Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Immuno-oncology Drugs Sales Quantity by Region
2.6.1 Global Immuno-oncology Drugs Sales Quantity by Region (2018-2024)
2.6.2 Global Immuno-oncology Drugs Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Immuno-oncology Drugs Sales Quantity by Manufacturers
3.1.1 Global Immuno-oncology Drugs Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Immuno-oncology Drugs Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Immuno-oncology Drugs Sales in 2022
3.2 Global Immuno-oncology Drugs Revenue by Manufacturers
3.2.1 Global Immuno-oncology Drugs Revenue by Manufacturers (2018-2024)
3.2.2 Global Immuno-oncology Drugs Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Immuno-oncology Drugs Revenue in 2022
3.3 Global Immuno-oncology Drugs Sales Price by Manufacturers
3.4 Global Key Players of Immuno-oncology Drugs, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Immuno-oncology Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Immuno-oncology Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Immuno-oncology Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Immuno-oncology Drugs Sales Quantity by Type
4.1.1 Global Immuno-oncology Drugs Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Immuno-oncology Drugs Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Immuno-oncology Drugs Sales Quantity Market Share by Type (2018-2034)
4.2 Global Immuno-oncology Drugs Revenue by Type
4.2.1 Global Immuno-oncology Drugs Historical Revenue by Type (2018-2024)
4.2.2 Global Immuno-oncology Drugs Forecasted Revenue by Type (2024-2034)
4.2.3 Global Immuno-oncology Drugs Revenue Market Share by Type (2018-2034)
4.3 Global Immuno-oncology Drugs Price by Type
4.3.1 Global Immuno-oncology Drugs Price by Type (2018-2024)
4.3.2 Global Immuno-oncology Drugs Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Immuno-oncology Drugs Sales Quantity by Application
5.1.1 Global Immuno-oncology Drugs Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Immuno-oncology Drugs Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Immuno-oncology Drugs Sales Quantity Market Share by Application (2018-2034)
5.2 Global Immuno-oncology Drugs Revenue by Application
5.2.1 Global Immuno-oncology Drugs Historical Revenue by Application (2018-2024)
5.2.2 Global Immuno-oncology Drugs Forecasted Revenue by Application (2024-2034)
5.2.3 Global Immuno-oncology Drugs Revenue Market Share by Application (2018-2034)
5.3 Global Immuno-oncology Drugs Price by Application
5.3.1 Global Immuno-oncology Drugs Price by Application (2018-2024)
5.3.2 Global Immuno-oncology Drugs Price Forecast by Application (2024-2034)
6 North America
6.1 North America Immuno-oncology Drugs Sales by Company
6.1.1 North America Immuno-oncology Drugs Revenue by Company (2018-2024)
6.1.2 North America Immuno-oncology Drugs Sales Quantity by Company (2018-2024)
6.2 North America Immuno-oncology Drugs Market Size by Type
6.2.1 North America Immuno-oncology Drugs Sales Quantity by Type (2018-2034)
6.2.2 North America Immuno-oncology Drugs Revenue by Type (2018-2034)
6.3 North America Immuno-oncology Drugs Market Size by Application
6.3.1 North America Immuno-oncology Drugs Sales Quantity by Application (2018-2034)
6.3.2 North America Immuno-oncology Drugs Revenue by Application (2018-2034)
6.4 North America Immuno-oncology Drugs Market Size by Country
6.4.1 North America Immuno-oncology Drugs Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Immuno-oncology Drugs Revenue by Country (2018-2034)
6.4.3 North America Immuno-oncology Drugs Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Immuno-oncology Drugs Sales by Company
7.1.1 Europe Immuno-oncology Drugs Sales Quantity by Company (2018-2024)
7.1.2 Europe Immuno-oncology Drugs Revenue by Company (2018-2024)
7.2 Europe Immuno-oncology Drugs Market Size by Type
7.2.1 Europe Immuno-oncology Drugs Sales Quantity by Type (2018-2034)
7.2.2 Europe Immuno-oncology Drugs Revenue by Type (2018-2034)
7.3 Europe Immuno-oncology Drugs Market Size by Application
7.3.1 Europe Immuno-oncology Drugs Sales Quantity by Application (2018-2034)
7.3.2 Europe Immuno-oncology Drugs Revenue by Application (2018-2034)
7.4 Europe Immuno-oncology Drugs Market Size by Country
7.4.1 Europe Immuno-oncology Drugs Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Immuno-oncology Drugs Revenue by Country (2018-2034)
7.4.3 Europe Immuno-oncology Drugs Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Immuno-oncology Drugs Sales by Company
8.1.1 China Immuno-oncology Drugs Sales Quantity by Company (2018-2024)
8.1.2 China Immuno-oncology Drugs Revenue by Company (2018-2024)
8.2 China Immuno-oncology Drugs Market Size by Type
8.2.1 China Immuno-oncology Drugs Sales Quantity by Type (2018-2034)
8.2.2 China Immuno-oncology Drugs Revenue by Type (2018-2034)
8.3 China Immuno-oncology Drugs Market Size by Application
8.3.1 China Immuno-oncology Drugs Sales Quantity by Application (2018-2034)
8.3.2 China Immuno-oncology Drugs Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Immuno-oncology Drugs Sales by Company
9.1.1 APAC Immuno-oncology Drugs Sales Quantity by Company (2018-2024)
9.1.2 APAC Immuno-oncology Drugs Revenue by Company (2018-2024)
9.2 APAC Immuno-oncology Drugs Market Size by Type
9.2.1 APAC Immuno-oncology Drugs Sales Quantity by Type (2018-2034)
9.2.2 APAC Immuno-oncology Drugs Revenue by Type (2018-2034)
9.3 APAC Immuno-oncology Drugs Market Size by Application
9.3.1 APAC Immuno-oncology Drugs Sales Quantity by Application (2018-2034)
9.3.2 APAC Immuno-oncology Drugs Revenue by Application (2018-2034)
9.4 APAC Immuno-oncology Drugs Market Size by Region
9.4.1 APAC Immuno-oncology Drugs Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Immuno-oncology Drugs Revenue by Region (2018-2034)
9.4.3 APAC Immuno-oncology Drugs Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Immuno-oncology Drugs Sales by Company
10.1.1 Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Immuno-oncology Drugs Market Size by Type
10.2.1 Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Immuno-oncology Drugs Market Size by Application
10.3.1 Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Immuno-oncology Drugs Market Size by Country
10.4.1 Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Amgen, Inc
11.1.1 Amgen, Inc Company Information
11.1.2 Amgen, Inc Overview
11.1.3 Amgen, Inc Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Amgen, Inc Immuno-oncology Drugs Products and Services
11.1.5 Amgen, Inc Immuno-oncology Drugs SWOT Analysis
11.1.6 Amgen, Inc Recent Developments
11.2 AstraZeneca, Plc
11.2.1 AstraZeneca, Plc Company Information
11.2.2 AstraZeneca, Plc Overview
11.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 AstraZeneca, Plc Immuno-oncology Drugs Products and Services
11.2.5 AstraZeneca, Plc Immuno-oncology Drugs SWOT Analysis
11.2.6 AstraZeneca, Plc Recent Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Information
11.3.2 Bristol-Myers Squibb Overview
11.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Products and Services
11.3.5 Bristol-Myers Squibb Immuno-oncology Drugs SWOT Analysis
11.3.6 Bristol-Myers Squibb Recent Developments
11.4 Celgene Corporation
11.4.1 Celgene Corporation Company Information
11.4.2 Celgene Corporation Overview
11.4.3 Celgene Corporation Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Celgene Corporation Immuno-oncology Drugs Products and Services
11.4.5 Celgene Corporation Immuno-oncology Drugs SWOT Analysis
11.4.6 Celgene Corporation Recent Developments
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Information
11.5.2 Eli Lilly and Company Overview
11.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Eli Lilly and Company Immuno-oncology Drugs Products and Services
11.5.5 Eli Lilly and Company Immuno-oncology Drugs SWOT Analysis
11.5.6 Eli Lilly and Company Recent Developments
11.6 Merck & Co.
11.6.1 Merck & Co. Company Information
11.6.2 Merck & Co. Overview
11.6.3 Merck & Co. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Merck & Co. Immuno-oncology Drugs Products and Services
11.6.5 Merck & Co. Immuno-oncology Drugs SWOT Analysis
11.6.6 Merck & Co. Recent Developments
11.7 Hoffmann-La Roche AG
11.7.1 Hoffmann-La Roche AG Company Information
11.7.2 Hoffmann-La Roche AG Overview
11.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Products and Services
11.7.5 Hoffmann-La Roche AG Immuno-oncology Drugs SWOT Analysis
11.7.6 Hoffmann-La Roche AG Recent Developments
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Information
11.8.2 Johnson & Johnson Overview
11.8.3 Johnson & Johnson Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Johnson & Johnson Immuno-oncology Drugs Products and Services
11.8.5 Johnson & Johnson Immuno-oncology Drugs SWOT Analysis
11.8.6 Johnson & Johnson Recent Developments
11.9 Novartis International AG
11.9.1 Novartis International AG Company Information
11.9.2 Novartis International AG Overview
11.9.3 Novartis International AG Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Novartis International AG Immuno-oncology Drugs Products and Services
11.9.5 Novartis International AG Immuno-oncology Drugs SWOT Analysis
11.9.6 Novartis International AG Recent Developments
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Information
11.10.2 AbbVie, Inc. Overview
11.10.3 AbbVie, Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 AbbVie, Inc. Immuno-oncology Drugs Products and Services
11.10.5 AbbVie, Inc. Immuno-oncology Drugs SWOT Analysis
11.10.6 AbbVie, Inc. Recent Developments
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Company Information
11.11.2 Pfizer Inc. Overview
11.11.3 Pfizer Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Pfizer Inc. Immuno-oncology Drugs Products and Services
11.11.5 Pfizer Inc. Recent Developments
11.12 Sanofi S.A.
11.12.1 Sanofi S.A. Company Information
11.12.2 Sanofi S.A. Overview
11.12.3 Sanofi S.A. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 Sanofi S.A. Immuno-oncology Drugs Products and Services
11.12.5 Sanofi S.A. Recent Developments
11.13 EMD Serono, Inc.
11.13.1 EMD Serono, Inc. Company Information
11.13.2 EMD Serono, Inc. Overview
11.13.3 EMD Serono, Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 EMD Serono, Inc. Immuno-oncology Drugs Products and Services
11.13.5 EMD Serono, Inc. Recent Developments
11.14 Gilead Sciences Inc.
11.14.1 Gilead Sciences Inc. Company Information
11.14.2 Gilead Sciences Inc. Overview
11.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.14.4 Gilead Sciences Inc. Immuno-oncology Drugs Products and Services
11.14.5 Gilead Sciences Inc. Recent Developments
11.15 Prometheus Therapeutics & Diagnostics
11.15.1 Prometheus Therapeutics & Diagnostics Company Information
11.15.2 Prometheus Therapeutics & Diagnostics Overview
11.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.15.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Products and Services
11.15.5 Prometheus Therapeutics & Diagnostics Recent Developments
11.16 Aduro BioTech
11.16.1 Aduro BioTech Company Information
11.16.2 Aduro BioTech Overview
11.16.3 Aduro BioTech Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.16.4 Aduro BioTech Immuno-oncology Drugs Products and Services
11.16.5 Aduro BioTech Recent Developments
11.17 Galena Biopharma
11.17.1 Galena Biopharma Company Information
11.17.2 Galena Biopharma Overview
11.17.3 Galena Biopharma Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.17.4 Galena Biopharma Immuno-oncology Drugs Products and Services
11.17.5 Galena Biopharma Recent Developments
11.18 Bavarian Nordic
11.18.1 Bavarian Nordic Company Information
11.18.2 Bavarian Nordic Overview
11.18.3 Bavarian Nordic Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.18.4 Bavarian Nordic Immuno-oncology Drugs Products and Services
11.18.5 Bavarian Nordic Recent Developments
11.19 Celldex Therapeutics
11.19.1 Celldex Therapeutics Company Information
11.19.2 Celldex Therapeutics Overview
11.19.3 Celldex Therapeutics Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.19.4 Celldex Therapeutics Immuno-oncology Drugs Products and Services
11.19.5 Celldex Therapeutics Recent Developments
11.20 ImmunoCellular Therapeutics
11.20.1 ImmunoCellular Therapeutics Company Information
11.20.2 ImmunoCellular Therapeutics Overview
11.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.20.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Products and Services
11.20.5 ImmunoCellular Therapeutics Recent Developments
11.21 Incyte
11.21.1 Incyte Company Information
11.21.2 Incyte Overview
11.21.3 Incyte Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.21.4 Incyte Immuno-oncology Drugs Products and Services
11.21.5 Incyte Recent Developments
11.22 Dendreon Corporation
11.22.1 Dendreon Corporation Company Information
11.22.2 Dendreon Corporation Overview
11.22.3 Dendreon Corporation Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.22.4 Dendreon Corporation Immuno-oncology Drugs Products and Services
11.22.5 Dendreon Corporation Recent Developments
11.23 Agilent Technologies Inc.
11.23.1 Agilent Technologies Inc. Company Information
11.23.2 Agilent Technologies Inc. Overview
11.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.23.4 Agilent Technologies Inc. Immuno-oncology Drugs Products and Services
11.23.5 Agilent Technologies Inc. Recent Developments
11.24 Agenus Inc.
11.24.1 Agenus Inc. Company Information
11.24.2 Agenus Inc. Overview
11.24.3 Agenus Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.24.4 Agenus Inc. Immuno-oncology Drugs Products and Services
11.24.5 Agenus Inc. Recent Developments
11.25 Enzo Biochem, Inc.
11.25.1 Enzo Biochem, Inc. Company Information
11.25.2 Enzo Biochem, Inc. Overview
11.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.25.4 Enzo Biochem, Inc. Immuno-oncology Drugs Products and Services
11.25.5 Enzo Biochem, Inc. Recent Developments
11.26 Lonza Group
11.26.1 Lonza Group Company Information
11.26.2 Lonza Group Overview
11.26.3 Lonza Group Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.26.4 Lonza Group Immuno-oncology Drugs Products and Services
11.26.5 Lonza Group Recent Developments
11.27 Bio-Rad Laboratories, Inc.
11.27.1 Bio-Rad Laboratories, Inc. Company Information
11.27.2 Bio-Rad Laboratories, Inc. Overview
11.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.27.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Products and Services
11.27.5 Bio-Rad Laboratories, Inc. Recent Developments
11.28 Avantor, Inc.
11.28.1 Avantor, Inc. Company Information
11.28.2 Avantor, Inc. Overview
11.28.3 Avantor, Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.28.4 Avantor, Inc. Immuno-oncology Drugs Products and Services
11.28.5 Avantor, Inc. Recent Developments
11.29 Spring Bank Pharmaceuticals, Inc.
11.29.1 Spring Bank Pharmaceuticals, Inc. Company Information
11.29.2 Spring Bank Pharmaceuticals, Inc. Overview
11.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.29.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Products and Services
11.29.5 Spring Bank Pharmaceuticals, Inc. Recent Developments
11.30 Ferring Pharmaceuticals
11.30.1 Ferring Pharmaceuticals Company Information
11.30.2 Ferring Pharmaceuticals Overview
11.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.30.4 Ferring Pharmaceuticals Immuno-oncology Drugs Products and Services
11.30.5 Ferring Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Immuno-oncology Drugs Value Chain Analysis
12.2 Immuno-oncology Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Immuno-oncology Drugs Production Mode & Process
12.4 Immuno-oncology Drugs Sales and Marketing
12.4.1 Immuno-oncology Drugs Sales Channels
12.4.2 Immuno-oncology Drugs Distributors
12.5 Immuno-oncology Drugs Customers
13 Market Dynamics
13.1 Immuno-oncology Drugs Industry Trends
13.2 Immuno-oncology Drugs Market Drivers
13.3 Immuno-oncology Drugs Market Challenges
13.4 Immuno-oncology Drugs Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Immune Checkpoint Inhibitors
Table 3. Major Manufacturers of Immune System Modulators
Table 4. Major Manufacturers of Cancer Vaccines
Table 5. Major Manufacturers of Oncolytic Virus
Table 6. Major Manufacturers of Others
Table 7. Global Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Immuno-oncology Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 9. Global Immuno-oncology Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 10. Global Immuno-oncology Drugs Revenue Market Share by Region (2018-2024)
Table 11. Global Immuno-oncology Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Immuno-oncology Drugs Revenue Market Share by Region (2024-2034)
Table 13. Global Immuno-oncology Drugs Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 14. Global Immuno-oncology Drugs Sales by Region (2018-2024) & (K Units)
Table 15. Global Immuno-oncology Drugs Sales Market Share by Region (2018-2024)
Table 16. Global Immuno-oncology Drugs Sales by Region (2024-2034) & (K Units)
Table 17. Global Immuno-oncology Drugs Sales Market Share by Region (2024-2034)
Table 18. Global Immuno-oncology Drugs Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 19. Global Immuno-oncology Drugs Sales Quantity Share by Manufacturers (2018-2024)
Table 20. Global Immuno-oncology Drugs Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 21. Global Immuno-oncology Drugs Revenue Share by Manufacturers (2018-2024)
Table 22. Global Immuno-oncology Drugs Price by Manufacturers 2018-2024 (USD/Unit)
Table 23. Global Key Players of Immuno-oncology Drugs, Industry Ranking, 2021 VS 2022
Table 24. Global Immuno-oncology Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Immuno-oncology Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immuno-oncology Drugs as of 2022)
Table 26. Global Key Manufacturers of Immuno-oncology Drugs, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Immuno-oncology Drugs, Product Offered and Application
Table 28. Global Key Manufacturers of Immuno-oncology Drugs, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Immuno-oncology Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 31. Global Immuno-oncology Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 32. Global Immuno-oncology Drugs Sales Quantity Share by Type (2018-2024)
Table 33. Global Immuno-oncology Drugs Sales Quantity Share by Type (2024-2034)
Table 34. Global Immuno-oncology Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 35. Global Immuno-oncology Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Immuno-oncology Drugs Revenue Share by Type (2018-2024)
Table 37. Global Immuno-oncology Drugs Revenue Share by Type (2024-2034)
Table 38. Immuno-oncology Drugs Price by Type (2018-2024) & (USD/Unit)
Table 39. Global Immuno-oncology Drugs Price Forecast by Type (2024-2034) & (USD/Unit)
Table 40. Global Immuno-oncology Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 41. Global Immuno-oncology Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 42. Global Immuno-oncology Drugs Sales Quantity Share by Application (2018-2024)
Table 43. Global Immuno-oncology Drugs Sales Quantity Share by Application (2024-2034)
Table 44. Global Immuno-oncology Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 45. Global Immuno-oncology Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Immuno-oncology Drugs Revenue Share by Application (2018-2024)
Table 47. Global Immuno-oncology Drugs Revenue Share by Application (2024-2034)
Table 48. Immuno-oncology Drugs Price by Application (2018-2024) & (USD/Unit)
Table 49. Global Immuno-oncology Drugs Price Forecast by Application (2024-2034) & (USD/Unit)
Table 50. North America Immuno-oncology Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 51. North America Immuno-oncology Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 52. North America Immuno-oncology Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 53. North America Immuno-oncology Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 54. North America Immuno-oncology Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 55. North America Immuno-oncology Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Immuno-oncology Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 57. North America Immuno-oncology Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 58. North America Immuno-oncology Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 59. North America Immuno-oncology Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Immuno-oncology Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 61. North America Immuno-oncology Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 62. North America Immuno-oncology Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Immuno-oncology Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 64. North America Immuno-oncology Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 65. Europe Immuno-oncology Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 66. Europe Immuno-oncology Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 67. Europe Immuno-oncology Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 68. Europe Immuno-oncology Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 69. Europe Immuno-oncology Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 70. Europe Immuno-oncology Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Immuno-oncology Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 72. Europe Immuno-oncology Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 73. Europe Immuno-oncology Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 74. Europe Immuno-oncology Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Immuno-oncology Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 76. Europe Immuno-oncology Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 77. Europe Immuno-oncology Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Immuno-oncology Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 79. Europe Immuno-oncology Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 80. China Immuno-oncology Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 81. China Immuno-oncology Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 82. China Immuno-oncology Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 83. China Immuno-oncology Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 84. China Immuno-oncology Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 85. China Immuno-oncology Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Immuno-oncology Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 87. China Immuno-oncology Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 88. China Immuno-oncology Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 89. China Immuno-oncology Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Immuno-oncology Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 91. APAC Immuno-oncology Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 92. APAC Immuno-oncology Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 93. APAC Immuno-oncology Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 94. APAC Immuno-oncology Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 95. APAC Immuno-oncology Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Immuno-oncology Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 97. APAC Immuno-oncology Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 98. APAC Immuno-oncology Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 99. APAC Immuno-oncology Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Immuno-oncology Drugs Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 101. APAC Immuno-oncology Drugs Revenue by Region (2018-2024) & (US$ Million)
Table 102. APAC Immuno-oncology Drugs Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Immuno-oncology Drugs Sales Quantity by Region (2018-2024) & (K Units)
Table 104. APAC Immuno-oncology Drugs Sales Quantity by Region (2024-2034) & (K Units)
Table 105. Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Company (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Type (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Type (2024-2034) & (K Units)
Table 109. Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Type (2018-2024) & (US$ Million)
Table 110. Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Application (2018-2024) & (K Units)
Table 112. Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Application (2024-2034) & (K Units)
Table 113. Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Application (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Country (2018-2024) & (US$ Million)
Table 117. Middle East, Africa and Latin America Immuno-oncology Drugs Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Country (2018-2024) & (K Units)
Table 119. Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity by Country (2024-2034) & (K Units)
Table 120. Amgen, Inc Company Information
Table 121. Amgen, Inc Description and Overview
Table 122. Amgen, Inc Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 123. Amgen, Inc Immuno-oncology Drugs Product and Services
Table 124. Amgen, Inc Immuno-oncology Drugs SWOT Analysis
Table 125. Amgen, Inc Recent Developments
Table 126. AstraZeneca, Plc Company Information
Table 127. AstraZeneca, Plc Description and Overview
Table 128. AstraZeneca, Plc Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 129. AstraZeneca, Plc Immuno-oncology Drugs Product and Services
Table 130. AstraZeneca, Plc Immuno-oncology Drugs SWOT Analysis
Table 131. AstraZeneca, Plc Recent Developments
Table 132. Bristol-Myers Squibb Company Information
Table 133. Bristol-Myers Squibb Description and Overview
Table 134. Bristol-Myers Squibb Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 135. Bristol-Myers Squibb Immuno-oncology Drugs Product and Services
Table 136. Bristol-Myers Squibb Immuno-oncology Drugs SWOT Analysis
Table 137. Bristol-Myers Squibb Recent Developments
Table 138. Celgene Corporation Company Information
Table 139. Celgene Corporation Description and Overview
Table 140. Celgene Corporation Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 141. Celgene Corporation Immuno-oncology Drugs Product and Services
Table 142. Celgene Corporation Immuno-oncology Drugs SWOT Analysis
Table 143. Celgene Corporation Recent Developments
Table 144. Eli Lilly and Company Company Information
Table 145. Eli Lilly and Company Description and Overview
Table 146. Eli Lilly and Company Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 147. Eli Lilly and Company Immuno-oncology Drugs Product and Services
Table 148. Eli Lilly and Company Immuno-oncology Drugs SWOT Analysis
Table 149. Eli Lilly and Company Recent Developments
Table 150. Merck & Co. Company Information
Table 151. Merck & Co. Description and Overview
Table 152. Merck & Co. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 153. Merck & Co. Immuno-oncology Drugs Product and Services
Table 154. Merck & Co. Immuno-oncology Drugs SWOT Analysis
Table 155. Merck & Co. Recent Developments
Table 156. Hoffmann-La Roche AG Company Information
Table 157. Hoffmann-La Roche AG Description and Overview
Table 158. Hoffmann-La Roche AG Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 159. Hoffmann-La Roche AG Immuno-oncology Drugs Product and Services
Table 160. Hoffmann-La Roche AG Immuno-oncology Drugs SWOT Analysis
Table 161. Hoffmann-La Roche AG Recent Developments
Table 162. Johnson & Johnson Company Information
Table 163. Johnson & Johnson Description and Overview
Table 164. Johnson & Johnson Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 165. Johnson & Johnson Immuno-oncology Drugs Product and Services
Table 166. Johnson & Johnson Immuno-oncology Drugs SWOT Analysis
Table 167. Johnson & Johnson Recent Developments
Table 168. Novartis International AG Company Information
Table 169. Novartis International AG Description and Overview
Table 170. Novartis International AG Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 171. Novartis International AG Immuno-oncology Drugs Product and Services
Table 172. Novartis International AG Immuno-oncology Drugs SWOT Analysis
Table 173. Novartis International AG Recent Developments
Table 174. AbbVie, Inc. Company Information
Table 175. AbbVie, Inc. Description and Overview
Table 176. AbbVie, Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 177. AbbVie, Inc. Immuno-oncology Drugs Product and Services
Table 178. AbbVie, Inc. Immuno-oncology Drugs SWOT Analysis
Table 179. AbbVie, Inc. Recent Developments
Table 180. Pfizer Inc. Company Information
Table 181. Pfizer Inc. Description and Overview
Table 182. Pfizer Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 183. Pfizer Inc. Immuno-oncology Drugs Product and Services
Table 184. Pfizer Inc. Recent Developments
Table 185. Sanofi S.A. Company Information
Table 186. Sanofi S.A. Description and Overview
Table 187. Sanofi S.A. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 188. Sanofi S.A. Immuno-oncology Drugs Product and Services
Table 189. Sanofi S.A. Recent Developments
Table 190. EMD Serono, Inc. Company Information
Table 191. EMD Serono, Inc. Description and Overview
Table 192. EMD Serono, Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 193. EMD Serono, Inc. Immuno-oncology Drugs Product and Services
Table 194. EMD Serono, Inc. Recent Developments
Table 195. Gilead Sciences Inc. Company Information
Table 196. Gilead Sciences Inc. Description and Overview
Table 197. Gilead Sciences Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 198. Gilead Sciences Inc. Immuno-oncology Drugs Product and Services
Table 199. Gilead Sciences Inc. Recent Developments
Table 200. Prometheus Therapeutics & Diagnostics Company Information
Table 201. Prometheus Therapeutics & Diagnostics Description and Overview
Table 202. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 203. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product and Services
Table 204. Prometheus Therapeutics & Diagnostics Recent Developments
Table 205. Aduro BioTech Company Information
Table 206. Aduro BioTech Description and Overview
Table 207. Aduro BioTech Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 208. Aduro BioTech Immuno-oncology Drugs Product and Services
Table 209. Aduro BioTech Recent Developments
Table 210. Galena Biopharma Company Information
Table 211. Galena Biopharma Description and Overview
Table 212. Galena Biopharma Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 213. Galena Biopharma Immuno-oncology Drugs Product and Services
Table 214. Galena Biopharma Recent Developments
Table 215. Bavarian Nordic Company Information
Table 216. Bavarian Nordic Description and Overview
Table 217. Bavarian Nordic Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 218. Bavarian Nordic Immuno-oncology Drugs Product and Services
Table 219. Bavarian Nordic Recent Developments
Table 220. Celldex Therapeutics Company Information
Table 221. Celldex Therapeutics Description and Overview
Table 222. Celldex Therapeutics Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 223. Celldex Therapeutics Immuno-oncology Drugs Product and Services
Table 224. Celldex Therapeutics Recent Developments
Table 225. ImmunoCellular Therapeutics Company Information
Table 226. ImmunoCellular Therapeutics Description and Overview
Table 227. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 228. ImmunoCellular Therapeutics Immuno-oncology Drugs Product and Services
Table 229. ImmunoCellular Therapeutics Recent Developments
Table 230. Incyte Company Information
Table 231. Incyte Description and Overview
Table 232. Incyte Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 233. Incyte Immuno-oncology Drugs Product and Services
Table 234. Incyte Recent Developments
Table 235. Dendreon Corporation Company Information
Table 236. Dendreon Corporation Description and Overview
Table 237. Dendreon Corporation Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 238. Dendreon Corporation Immuno-oncology Drugs Product and Services
Table 239. Dendreon Corporation Recent Developments
Table 240. Agilent Technologies Inc. Company Information
Table 241. Agilent Technologies Inc. Description and Overview
Table 242. Agilent Technologies Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 243. Agilent Technologies Inc. Immuno-oncology Drugs Product and Services
Table 244. Agilent Technologies Inc. Recent Developments
Table 245. Agenus Inc. Company Information
Table 246. Agenus Inc. Description and Overview
Table 247. Agenus Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 248. Agenus Inc. Immuno-oncology Drugs Product and Services
Table 249. Agenus Inc. Recent Developments
Table 250. Enzo Biochem, Inc. Company Information
Table 251. Enzo Biochem, Inc. Description and Overview
Table 252. Enzo Biochem, Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 253. Enzo Biochem, Inc. Immuno-oncology Drugs Product and Services
Table 254. Enzo Biochem, Inc. Recent Developments
Table 255. Lonza Group Company Information
Table 256. Lonza Group Description and Overview
Table 257. Lonza Group Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 258. Lonza Group Immuno-oncology Drugs Product and Services
Table 259. Lonza Group Recent Developments
Table 260. Bio-Rad Laboratories, Inc. Company Information
Table 261. Bio-Rad Laboratories, Inc. Description and Overview
Table 262. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 263. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product and Services
Table 264. Bio-Rad Laboratories, Inc. Recent Developments
Table 265. Avantor, Inc. Company Information
Table 266. Avantor, Inc. Description and Overview
Table 267. Avantor, Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 268. Avantor, Inc. Immuno-oncology Drugs Product and Services
Table 269. Avantor, Inc. Recent Developments
Table 270. Spring Bank Pharmaceuticals, Inc. Company Information
Table 271. Spring Bank Pharmaceuticals, Inc. Description and Overview
Table 272. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 273. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product and Services
Table 274. Spring Bank Pharmaceuticals, Inc. Recent Developments
Table 275. Ferring Pharmaceuticals Company Information
Table 276. Ferring Pharmaceuticals Description and Overview
Table 277. Ferring Pharmaceuticals Immuno-oncology Drugs Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 278. Ferring Pharmaceuticals Immuno-oncology Drugs Product and Services
Table 279. Ferring Pharmaceuticals Recent Developments
Table 280. Key Raw Materials Lists
Table 281. Raw Materials Key Suppliers Lists
Table 282. Immuno-oncology Drugs Distributors List
Table 283. Immuno-oncology Drugs Customers List
Table 284. Immuno-oncology Drugs Market Trends
Table 285. Immuno-oncology Drugs Market Drivers
Table 286. Immuno-oncology Drugs Market Challenges
Table 287. Immuno-oncology Drugs Market Restraints
Table 288. Research Programs/Design for This Report
Table 289. Key Data Information from Secondary Sources
Table 290. Key Data Information from Primary Sources
List of Figures
Figure 1. Immuno-oncology Drugs Product Picture
Figure 2. Global Immuno-oncology Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Immuno-oncology Drugs Market Share by Type in 2022 & 2034
Figure 4. Immune Checkpoint Inhibitors Product Picture
Figure 5. Immune System Modulators Product Picture
Figure 6. Cancer Vaccines Product Picture
Figure 7. Oncolytic Virus Product Picture
Figure 8. Others Product Picture
Figure 9. Global Immuno-oncology Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 10. Global Immuno-oncology Drugs Market Share by Application in 2022 & 2034
Figure 11. Hospitals
Figure 12. Clinics
Figure 13. Ambulatory Surgical Centers
Figure 14. Immuno-oncology Drugs Report Years Considered
Figure 15. Global Immuno-oncology Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global Immuno-oncology Drugs Revenue 2018-2034 (US$ Million)
Figure 17. Global Immuno-oncology Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 18. Global Immuno-oncology Drugs Sales Quantity 2018-2034 (K Units)
Figure 19. Global Immuno-oncology Drugs Sales Quantity Market Share by Region (2018-2024)
Figure 20. Global Immuno-oncology Drugs Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Immuno-oncology Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. North America Immuno-oncology Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Immuno-oncology Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. Europe Immuno-oncology Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Immuno-oncology Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. China Immuno-oncology Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Immuno-oncology Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. APAC Immuno-oncology Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Immuno-oncology Drugs Sales Quantity YoY (2018-2034) & (K Units)
Figure 30. Middle East, Africa and Latin America Immuno-oncology Drugs Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Immuno-oncology Drugs Sales Quantity in 2022
Figure 32. The Top 10 and Top 5 Players Market Share by Immuno-oncology Drugs Revenue in 2022
Figure 33. Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 34. Global Immuno-oncology Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Immuno-oncology Drugs Revenue Market Share by Type (2018-2034)
Figure 36. Global Immuno-oncology Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Immuno-oncology Drugs Revenue Market Share by Application (2018-2034)
Figure 38. North America Immuno-oncology Drugs Revenue Market Share by Company in 2022
Figure 39. North America Immuno-oncology Drugs Sales Quantity Market Share by Company in 2022
Figure 40. North America Immuno-oncology Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Immuno-oncology Drugs Revenue Market Share by Type (2018-2034)
Figure 42. North America Immuno-oncology Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Immuno-oncology Drugs Revenue Market Share by Application (2018-2034)
Figure 44. North America Immuno-oncology Drugs Revenue Share by Country (2018-2034)
Figure 45. North America Immuno-oncology Drugs Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. Immuno-oncology Drugs Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Immuno-oncology Drugs Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Immuno-oncology Drugs Sales Quantity Market Share by Company in 2022
Figure 49. Europe Immuno-oncology Drugs Revenue Market Share by Company in 2022
Figure 50. Europe Immuno-oncology Drugs Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Immuno-oncology Drugs Revenue Market Share by Type (2018-2034)
Figure 52. Europe Immuno-oncology Drugs Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Immuno-oncology Drugs Revenue Market Share by Application (2018-2034)
Figure 54. Europe Immuno-oncology Drugs Revenue Share by Country (2018-2034)
Figure 55. Europe Immuno-oncology Drugs Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Immuno-oncology Drugs Revenue (2018-2034) & (US$ Million)
Figure 57. France Immuno-oncology Drugs Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. Immuno-oncology Drugs Revenue (2018-2034) & (US$ Million)
Figure 59. Italy Immuno-oncology Drugs Revenue (2018-2034) & (US$ Million)
Figure 60. Russia Immuno-oncology Drugs Revenue (2018-2034) & (US$ Million)
Figure 61. China Immuno-oncology Drugs Sales Quantity Market Share by Company in 2022
Figure 62. China Immuno-oncology Drugs Revenue Mark